COVID-19
Withdrawn applications
Vaccine developers have withdrawn the following COVID-19 vaccines from the rolling review process:
| Vaccine | Vaccine developer | Key milestones | More information |
|---|---|---|---|
| CVnCoV | CureVac AG | Rolling review started: 12/02/2021 Withdrawn from rolling review: 12/10/2021 |
Vaccine developers have withdrawn the following COVID-19 vaccines from the marketing authorisation evaluation process:
| Vaccine | Vaccine developer | Key milestones | More information |
|---|---|---|---|
| Skycovion | SK Chemicals GmbH | Marketing authorisation evaluation started: 18/08/2022 Withdrawn from marketing authorisation evaluation: 01/09/2023 | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023 |
Treatment developers have withdrawn the following COVID-19 treatments from the marketing authorisation evaluation process:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| Olumiant (baricitinib) | Eli Lilly Nederland B.V. | Marketing authorisation evaluation started: 23/11/2021 Withdrawn from marketing authorisation evaluation: 07/12/2022 | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022 |
| Lagevrio (molnupiravir) | Merck Sharp & Dohme and Ridgeback Biotherapeutics | Marketing authorisation evaluation started: 23/11/2021 CHMP negative opinion: 23/02/2023 Re-examination request submitted: 13/03/2023 Withdrawn from marketing authorisation evaluation: 21/06/2023 |
Treatment developers have withdrawn the following COVID-19 treatments from the rolling review process:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| Bamlanivimab and etesevimab | Eli Lilly | Rolling review started: 11/03/2021 Withdrawn from rolling review: 29/10/2021 | Latest news Paediatric investigation plan for bamlanivimab Paediatric investigation plan for etesevimab |